Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Review. Molecular background of chemoresistance in pancreatic cancer.

In vivo (Athens, Greece) - 1 Jan 2000

Zalatnai Attila, Molnár József

Abstract excerpt

The survival data of patients with ductal pancreatic adenocarcinoma are rather poor, partly because the disease is frequently diagnosed at an advanced stage, partly because it is characterized by a chemoresistant phenotype. Even first-line chemotherapeutic drugs result in a modest objective respo...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to ATP-Binding Cassette Transporters
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pancreatic Neoplasms

Share to Phenotype

Source

Identifiers

PMID: 17436586

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17436586-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Review. Molecular background of chemoresistance in pancreatic cancer.PMID 17436586Read ↗

The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overviewSemantic proximity Read ↗

Challenges of drug resistance in the management of pancreatic cancerSemantic proximity Read ↗

The Landscape of Pancreatic Cancer Therapeutic Resistance MechanismsSemantic proximity Read ↗

Overcoming drug resistance in pancreatic cancer.Semantic proximity Read ↗

Overcoming therapeutic resistance in pancreatic cancer: Emerging opportunities by targeting BRCAs and p53Semantic proximity Read ↗

Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels.Semantic proximity Read ↗

ATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: What is the way forward?Semantic proximity Read ↗

Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.Semantic proximity Read ↗

Multidrug resistance genes screening of pancreatic cancer based on sensitivity profile to chemotherapeutic drugsSemantic proximity Read ↗

Multidrug resistance genes screening of pancreatic ductal adenocarcinoma based on sensitivity profile to chemotherapeutic drugsSemantic proximity Read ↗

Pancreatic cancer chemo-resistance is driven by tumor phenotype rather than tumor genotypeSemantic proximity Read ↗

Molecular alterations contributing to pancreatic cancer chemoresistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.